Abu dhabi: M42 and Global Medical Supply Chain (GMSC), a subsidiary of Mubadala Bio, have entered into an outsourcing agreement to strengthen medical supply chain services across M42's healthcare network.
According to Emirates News Agency, the agreement was signed on the sidelines of Make it in the Emirates (MIITE) 2026, the UAE's flagship industrial platform. This collaboration reflects both organisations' commitment to supporting the UAE's priorities to localise critical industries, strengthen supply chain resilience, and build a future-ready healthcare system.
The agreement was executed by Dimitris Moulavasilis, Group Chief Executive Officer of M42, and Hamad Husein Al Marzooqi, Deputy Chief Executive Officer of Mubadala Bio. The signing was witnessed by Sheikh Zayed bin Mansour bin Tahnoon Al Nahyan, Head of Strategic Collaborations at M42, and Dr. Bakheet Al Katheeri, Chief Executive Officer of Mubadala's UAE Investments platform.
Under the agreement, GMSC will manage a fully integrated supply chain model across M42's network, covering sourcing and procurement, demand planning, warehousing, distribution, and inventory management. The partnership spans pharmaceuticals, medical consumables, equipment, and instruments, ensuring reliable and consistent supply across healthcare facilities.
Dr. Bakheet Al Katheeri highlighted that the agreement is a significant step forward for Mubadala in supporting the UAE's ambition to build a globally leading, self-sustaining healthcare and life sciences ecosystem. By combining Mubadala Bio's specialised capabilities with M42's scale, the collaboration aims to strengthen supply chain resilience and accelerate the development of in-country capabilities that will underpin long-term national health security, industrial growth, and global competitiveness.
Dimitris Moulavasilis stated that a resilient and integrated supply chain is fundamental to M42's health intelligence ecosystem. The partnership with Mubadala Bio's GMSC is an important step in M42's transformation journey, enhancing the ability to deliver high-quality, patient-centric care with greater operational efficiency while supporting the UAE's supply chain resilience and localisation ambitions.
Hamad Husein Al Marzooqi expressed that the partnership agreement with M42 reflects Mubadala Bio's commitment to delivering end-to-end pharmaceutical logistics across the UAE. Through GMSC, more integrated and resilient supply chain systems are being enabled, ensuring healthcare providers have reliable access to high-quality medical products. The collaboration supports M42's extensive network of world-class healthcare facilities.
As part of the agreement, GMSC will work closely with M42's clinical and operational teams to optimise demand forecasting, improve procurement efficiency, and enhance inventory visibility across the network. The collaboration is expected to improve service reliability, reduce supply disruption risks, and drive cost efficiencies at scale.